Chugai Pharmaceutical Co., Ltd. (4519) Press Release
CONSOLIDATED FINANCIAL STATEMENTS (IFRS) (Non-Audited) (for the six months ended June 30, 2026)
Earlier from Chugai Pharmaceutical
- F. Hoffmann-La Roche Announces Half Year Results 2026
- Chugai Files New Drug Application in Japan for Sparsentan for the Treatment of IgA Nephropathy
- Chugai Receives The Imperial Invention Prize, the Highest Honor of the FY2026 National Commendation for Invention, Recycling Antibody Technology Recognized for its Contribution to Pharmaceutical Research
- Chugai Pharmaceutical: Alecensa Receives the World-First Tumor-Agnostic Approval for ALK Fusion Gene-Positive Solid Tumors Across Adult and Pediatric Patients